Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096798 · ClinicalTrials.gov registry record · Phase 3
Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression
A Phase 3 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
NCT00096798: Completed Phase 3 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
NCT00096798 is a Phase 3 study that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 80 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096798, a Phase 3 study, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effectiveness of ethyl-eicosapentanoic acid (ethyl-EPA), an omega-3 fatty acid, in treating depression.
Interventions
- DRUG Ethyl-eicosapentanoic acid (ethyl-EPA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2001-09 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
What the finished NCT00096798 record still lists
NCT00096798 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Ethyl-eicosapentanoic acid (ethyl-EPA) is the first listed.
NCT00096798 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00096798 about?
NCT00096798 is a clinical study titled "Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression". The purpose of this study is to examine the effectiveness of ethyl-eicosapentanoic acid (ethyl-EPA), an omega-3 fatty acid, in treating depression.
What is the current status of trial NCT00096798?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2001-09. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00096798?
The interventions under investigation include: Ethyl-eicosapentanoic acid (ethyl-EPA) (DRUG).
Who is sponsoring clinical trial NCT00096798?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00096798's enrollment target sits among peer trials
80 1755th of 2000 higher than 233 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia